Showing results (41-50 of 187) with videos related to

Sort By:
Pageof 19
Clinical Endocrinology|December 11, 2008
Use of a GH receptor antagonist (GHRA) to explore the relationship between GH and IGF-I in adults with severe GH deficiency (GHD)C A Berg, A Pokrajac, M Bidlingmaier, et al.
The Journal of Clinical Endocrinology and Metabolism|April 5, 2002
A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed mealC Parkinson, W M Drake, M E Roberts, et al.
Clinical Endocrinology|July 1, 1994
An audit of the insulin tolerance test in adult subjects in an acute investigation unit over one yearS L Jones, P J Trainer, L Perry, et al.
The Quarterly Journal of Medicine|September 1, 1992
Possible mechanism and treatment of o,p'DDD-induced hypercholesterolaemiaV M Maher, P J Trainer, A Scoppola, et al.
Growth Regulation|June 1, 1996
Insulin-like growth factor-I and- II in combination inhibit the release of growth hormone-releasing hormone from the rat hypothalamus in vitroM Korbonits, J A Little, C Camacho-Hübner, et al.
European Journal of Endocrinology|October 3, 2001
Successful treatment of resistant acromegaly with a growth hormone receptor antagonistW M Drake, C Parkinson, S A Akker, et al.
Clinical Endocrinology|October 1, 1994
Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocityJ M Kirk, P J Trainer, W H Majrowski, et al.
British Journal of Cancer|September 1, 1999
Adrenal enlargement and failure of suppression of circulating cortisol by dexamethasone in patients with malignancyP J Jenkins, S A Sohaib, P J Trainer, et al.
Clinical Endocrinology|June 4, 2016
Proopiomelanocortin interference in the measurement of adrenocorticotrophic hormone: a United Kingdom National External Quality Assessment Service studyP J Monaghan, A Kyriacou, C Sturgeon, et al.
European Journal of Endocrinology|March 15, 2005
Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomantW M Drake, R A Loureiro, C Parkinson, et al.
Pageof 19